Stratos Wealth Partners LTD. Sells 727 Shares of Zoetis Inc. $ZTS

Stratos Wealth Partners LTD. lessened its stake in Zoetis Inc. (NYSE:ZTS) by 1.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 65,157 shares of the company’s stock after selling 727 shares during the period. Stratos Wealth Partners LTD.’s holdings in Zoetis were worth $10,161,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Nova Wealth Management Inc. bought a new stake in shares of Zoetis in the 1st quarter valued at about $25,000. 1248 Management LLC bought a new stake in shares of Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank bought a new stake in shares of Zoetis in the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC grew its position in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after buying an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC grew its position in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.6%

ZTS stock opened at $144.15 on Friday. The stock’s 50 day simple moving average is $148.73 and its 200 day simple moving average is $153.76. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $193.49. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market cap of $63.88 billion, a P/E ratio of 24.81, a price-to-earnings-growth ratio of 2.30 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the prior year, the business earned $1.56 EPS. The firm’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio is 34.42%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on ZTS shares. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Leerink Partners downgraded Zoetis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Argus reissued a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $196.71.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.